Linear dipeptidyl peptidase 1 inhibitors and uses thereof

A compound of Formula (IX),

• or a pharmaceutically acceptable salt, a stereoisomer or a deuterated form thereof, wherein:
• R1 is carbocyclyl, aryl, heterocyclyl or heteroaryl, wherein R1 is optionally substituted with 1-5 groups independently selected from R5 or R6;
• L is arylene, heterocyclylene, heteroarylene or cycloalkylene, wherein L is optionally substituted by 1-4 R7;
• each R2 is independently H, halogen, —OH, —CN, —Oalkyl, -NH2, —SH, —C(═O)alkyl, -C(═O)NH2, alkyl, haloalkyl, -alkylene-OH, -alkylene-CH (COOH)(NH2), alkenyl, alkynyl, -S(alkyl), —S(═O)alkyl, —S(═O)2alkyl, carbocyclyl, heterocyclyl, aryl, heteroaryl, alkylene-aryl, alkylene-heteroaryl, alkylene-heterocyclyl or alkylene-carbocyclyl, wherein R2 is optionally substituted with 1-4 R2a, provided that at least one R2 is not H;
• or two R2 together form (═O);
• R3 is H, alkyl, cycloalkyl, aryl, heterocyclyl, heteroaryl, -alkylene-OH, -alkylene-O-alkyl, -alkylene-carbocyclyl, -alkylene-heterocyclyl, -alkylene-aryl, -alkylene-heteroaryl, —C(═O)alkyl, —C(═O) cycloalkyl, —C(═O)aryl or -C(═O) heteroaryl, wherein R3 is optionally substituted with 1-4 R3a;
• R4 is C1-6 alkyl;
• or R3 and R4 together with the nitrogen to which they are attached form a heterocyclyl, wherein the heterocyclyl is optionally substituted with 1-4 R3a;
• each of R2a and R3a is independently alkyl, halogen, haloalkyl, —Oalkyl, —OH, —CN, -C(═O)OH, —NH2, —NH(alkyl), —NH(alkyl)2, cycloalkyl or heterocyclyl;
• each R5 is independently halogen, C1-6 alkyl, —O (C1-6 alkyl), C1-6 haloalkyl, C2-6 alkenyl, C2-6 alkynyl, C3-6 cycloalkyl, —CN, oxo, —OH, —NH2, —NHC1-6 alkyl, —N(C1-6 alkyl)2, -COOH, -C(═O)(C1-6 alkyl), —C(═O)O (C1-6 alkyl), —C(═O)NH(C1-6 alkyl), C(═O)N (C1-6 alkyl)2, NHC(═O)(C1-6 alkyl), —S(═O)2(C1-6 alkyl), -(C1-6 alkylene)-cycloalkyl, —S(═O)2-cycloalkyl, -(C1-6 alkylene)-heterocyclyl, —S(═O)2-heterocyclyl, -heterocyclylene-heterocyclyl or heterocyclyl, wherein each R5 is optionally substituted with 1-3 groups selected from halogen, —CN, —OH, —NH2, C1-6 alkyl, —O (C1-6 alkyl), -COOH, cycloalkyl or heterocyclyl;
• each R6 is independently H, C1-6 alkyl, -(C1-6 alkylene)-O-(C1-6 alkyl), -(C1-6 alkylene)-NH2, -(C1-6 alkylene)-NH(C1-6 alkyl)2, -C1-6 alkylene-N(C1-6 alkyl)2, -C1-6 alkylene-NH(C1-6 alkylene-O-C1-6 alkyl), -C1-6 alkylene-N(C1-6 alkylene-O-C1-6 alkyl)(C1-6 alkyl), -C1-6 alkylene-heterocyclyl, C(═O)(C1-6 alkyl), C2-6 alkenyl, C2-6 alkynyl, C3-6 cycloalkyl, -heterocyclylene-heterocyclyl or heterocyclyl, wherein each R6 is optionally substituted with 1-3 groups selected from halogen, —CN, —OH, C1-6 alkyl, —O (C1-6 alkyl), —NH2, —NH(C1-6 alkyl), —N(C1-6 alkyl)2, cycloalkyl, aryl, heterocyclyl, heteroaryl or -COOH;
• and
• each R7 is independently ═O, halogen, C1-6 alkyl, —O (C1-6 alkyl), —S(C1-6 alkyl), C2-6 alkenyl, C2-6 alkynyl, C3-6 cycloalkyl, —CN, —OH, —NH2, —NH(C1-6 alkyl), —N(C1-6 alkyl)2, -COOH, -C(═O)(C1-6 alkyl), —C(═O)O (C1-6 alkyl), —C(═O)N (C1-6 alkyl)2, or —NHC(═O)(C1-6 alkyl);
• or one R7 and one R5 together form a carbocyclyl, aryl, heterocyclyl or heteroaryl ring, wherein the carbocyclyl, aryl, heterocyclyl, heteroaryl is optionally substituted with 1-4 groups selected from C1-6 alkyl, halogen, —OC1-6 alkyl, haloalkyl, —OH, —CN, or heterocyclyl.